Cabazitaxel Schedules in Metastatic Castration-Resistant Prostate Cancer: A Review

References

• American Cancer Society . Global Cancer Facts & Figures4th Edition. USA (2012). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-4th-edition.pdf
   Google Scholar
• Tannock IF , de WitR, BerryWRet al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak DP , TangenCM, HussainMHAet al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Oudard S , FizaziK, SengeløvLet al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized Phase III trial – FIRSTANA. J. Clin. Oncol.35(28), 3189–3197 (2017).
   PubMed Web of Science ®Google Scholar
• Perez EA . Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol. Cancer Ther.8(8), 2086–2095 (2009).
   PubMed Web of Science ®Google Scholar
• Vrignaud P , SémiondD, LejeunePet al. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin. Cancer Res.19(11), 2973–2983 (2013).
   PubMed Web of Science ®Google Scholar
• de Bono JS , OudardS, OzgurogluMet al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet376(9747), 1147–1154 (2010).
   PubMed Web of Science ®Google Scholar
• Boyle HJ , AlibhaiS, DecosterLet al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur. J. Cancer116, 116–136 (2019).
   PubMed Web of Science ®Google Scholar
• de Wit R , de BonoJ, SternbergCNet al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl J. Med.381, 2506–2518 (2019).
   PubMed Web of Science ®Google Scholar
• Scosyrev E , MessingEM, MohileS, GolijaninD, WuG. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer118(12), 3062–3070 (2012).
   PubMedGoogle Scholar
• Lissbrant IF , GarmoH, WidmarkA, StattinP. Population-based study on use of chemotherapy in men with castration-resistant prostate cancer. Acta Oncol.52(8), 1593–1601 (2013).
   PubMed Web of Science ®Google Scholar
• Attard G , BorreM, GurneyHet al. Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J. Clin. Oncol.36(25), 2639–2646 (2018).
   PubMed Web of Science ®Google Scholar
• de Bono J , MateoJ, FizaziKet al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl J. Med.382, 2091–2102 (2020).
   PubMed Web of Science ®Google Scholar
• Heidenreich A , BracardaS, MasonMet al. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur. J. Cancer50(6), 1090–1099 (2014).
   PubMed Web of Science ®Google Scholar
• Bahl A , OudardS, TombalBet al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann. Oncol.24(9), 2402–2408 (2013).
   PubMed Web of Science ®Google Scholar
• Eisenberger M , Hardy-BessardA-C, KimCSet al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer – PROSELICA. J. Clin. Oncol.35(28), 3198–3206 (2017).
   PubMed Web of Science ®Google Scholar
• Ryan CJ , SmithMR, FizaziKet al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol.16(2), 152–160 (2015).
   PubMed Web of Science ®Google Scholar
• Beer TM , ArmstrongAJ, RathkopfDet al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the Phase 3 PREVAIL study. Eur. Urol.71(2), 151–154 (2017).
   PubMed Web of Science ®Google Scholar
• Robbrecht DG , DelanoyN, TannockIFet al. Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. Eur. J. Cancer125, 142–152 (2020).
   PubMed Web of Science ®Google Scholar
• Beer TM , HotteSJ, SaadFet al. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, Phase 3 trial. Lancet Oncol.18(11), 1532–1542 (2017).
   PubMed Web of Science ®Google Scholar
• Fizazi K , KramerG, EymardJ-Cet al. Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study. J. Clin. Oncol.38(Suppl. 6), S16–S16 (2020).
   Web of Science ®Google Scholar
• Clément-Zhao A , AuvrayM, AboudaggaHet al. Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer. BJU Int.121(2), 203–208 (2018).
   PubMed Web of Science ®Google Scholar
• Sternberg CN , CastellanoD, DeBono JSet al. Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study. J. Clin. Oncol.38(Suppl. 15), S5559–S5559 (2020).
   Web of Science ®Google Scholar
• Mottet N , BellmuntJ, BollaMet al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol.71(4), 618–629 (2017).
   PubMed Web of Science ®Google Scholar
• Droz J-P , EfstathiouE, YildirimAet al. First-line treatment in senior adults with metastatic castration-resistant prostate cancer: a prospective international registry. Urol. Oncol.34(5), 234.e21–29 (2016).
   PubMed Web of Science ®Google Scholar
• Kellokumpu-Lehtinen P-L , HarmenbergU, JoensuuTet al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, Phase 3 trial. Lancet Oncol.14(2), 117–124 (2013).
   PubMed Web of Science ®Google Scholar
• Kellokumpu-Lehtinen P-L , MarttilaT, JekunenAPet al. Biweekly cabazitaxel as a safe treatment option for metastatic castration resistant prostate cancer (mCRPC) patients post-docetaxel: final analysis of Prosty II trial. J. Clin. Oncol.34(Suppl. 15), e16523–e16523 (2016).
   Google Scholar
• Climent MÁ , Pérez-ValderramaB, MelladoBet al. Weekly cabazitaxel plus prednisone is effective and less toxic for “unfit” metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. Eur. J. Cancer87, 30–37 (2017).
   PubMed Web of Science ®Google Scholar
• Yachnin J , GiljeB, ThonKet al. Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: a randomised Phase II trial (ConCab). Eur. J. Cancer97, 33–40 (2018).
   PubMed Web of Science ®Google Scholar
• Bahl A , MassonS, MalikZet al. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK early access programme (EAP) (NCT01254279). BJU Int.116(6), 880–887 (2015).
   PubMed Web of Science ®Google Scholar
• Carles J , PichlerA, KorunkovaHet al. An observational multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). BJU Int.123(3), 456–464 (2019).
   PubMed Web of Science ®Google Scholar
• Rouyer M , OudardS, JolyFet al. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort. Br. J. Cancer121(12), 1001–1008 (2019).
   PubMed Web of Science ®Google Scholar
• Joly F , OudardS, FizaziKet al. Quality of life and pain during treatment of metastatic castration-resistant prostate cancer with cabazitaxel in routine clinical practice. Clin. Genitourin. Cancer S1558-7673(20)30037-9 (2020).
   PubMedGoogle Scholar
• Pollard ME , MoskowitzAJ, DiefenbachMA, HallSJ. Cost-effectiveness analysis of treatments for metastatic castration-resistant prostate cancer. Asian J. Urol.4(1), 37–43 (2017).
   PubMed Web of Science ®Google Scholar
• Kearns B , PandorA, StevensonMet al. Cabazitaxel for hormone-relapsed metastatic prostate cancer previously treated with a docetaxel-containing regimen: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics35(4), 415–424 (2017).
   PubMed Web of Science ®Google Scholar
• Flannery K , DreaE, HudspethLet al. Budgetary impact of cabazitaxel use after docetaxel treatment for metastatic castration-resistant prostate cancer. J. Manag. Care Spec. Pharm.23(4), 416–426 (2017).
   PubMedGoogle Scholar
• Wen L , ValderramaA, CostantinoME, SimmonsS. Real-world treatment patterns in patients with castrate-resistant prostate cancer and bone metastases. Am. Health Drug Benefits12(3), 142–149 (2019).
   PubMed Web of Science ®Google Scholar
• Mohler J , BahnsonRR, BostonBet al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl Compr. Canc. Netw.8(2), 162–200 (2010).
   PubMed Web of Science ®Google Scholar
• Parker C , GillessenS, HeidenreichA, HorwichA. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.26(Suppl. 5), v69–v77 (2015).
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G , BracardaS, BuonerbaC, AietaM, MironeV. Poor survival in prostate cancer patients with primary refractoriness to docetaxel. Eur. Urol.65(2), 505–507 (2014).
   PubMed Web of Science ®Google Scholar
• van Soest RJ , NieuweboerAJM, de MorréeESet al. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. Eur. J. Cancer51(17), 2562–2569 (2015).
   PubMed Web of Science ®Google Scholar
• Delanoy N , Hardy-BessardA-C, EfstathiouEet al. Sequencing of taxanes and new androgen-targeted therapies in metastatic castration-resistant prostate cancer: results of the international multicentre retrospective CATS database. Eur. Urol. Oncol.1(6), 467–475 (2018).
   PubMed Web of Science ®Google Scholar
• Parker C , NilssonS, HeinrichDet al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl J. Med.369(3), 213–223 (2013).
   PubMed Web of Science ®Google Scholar
• Sartor O , ColemanR, NilssonSet al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a Phase 3, double-blind, randomised trial. Lancet Oncol.15(7), 738–746 (2014).
   PubMed Web of Science ®Google Scholar
• Powell DR , HuttenlocherA. Neutrophils in the tumor microenvironment. Trends Immunol.37(1), 41–52 (2016).
   PubMed Web of Science ®Google Scholar
• Templeton AJ , McNamaraMG, ŠerugaBet al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J. Natl Cancer Inst.106(6), dju124 (2014).
   PubMedGoogle Scholar
• Shitara K , MatsuoK, OzeIet al. Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother. Pharmacol.68(2), 301–307 (2011).
   PubMed Web of Science ®Google Scholar
• Zhou T , ZengS, YeDet al. A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantrone plus prednisone for Chinese patients with metastatic castration-refractory prostate cancer. PLoS One10(1), e0117002 (2015).
   PubMed Web of Science ®Google Scholar
• Meisel A , von FeltenS, VogtDRet al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC Phase III trial. Eur. J. Cancer56, 93–100 (2016).
   PubMed Web of Science ®Google Scholar